Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 59 citing articles:

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
Sinja Taavitsainen, Nikolai Engedal, Shaolong Cao, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 92
Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it
Yuanyuan Wang, Jiyuan Chen, Zhengjie Wu, et al.
British Journal of Pharmacology (2020) Vol. 178, Iss. 2, pp. 239-261
Open Access | Times Cited: 83
Understanding and targeting prostate cancer cell heterogeneity and plasticity
Dean G. Tang
Seminars in Cancer Biology (2021) Vol. 82, pp. 68-93
Open Access | Times Cited: 61
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
Mark C. Markowski, Mary‐Ellen Taplin, Rahul Aggarwal, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications
Rajendra Kumar, Laura A. Sena, Samuel R. Denmeade, et al.
Nature Reviews Urology (2022) Vol. 20, Iss. 5, pp. 265-278
Open Access | Times Cited: 35
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
Laura A. Sena, Rajendra Kumar, David E. Sanin, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 23
Open Access | Times Cited: 34
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study
Fady Ghali, Funda Vakar‐Lopez, Martine P. Roudier, et al.
Clinical Genitourinary Cancer (2023) Vol. 21, Iss. 6, pp. 669-678
Open Access | Times Cited: 19
Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor
Remi Adelaiye‐Ogala, Berkley E. Gryder, Yen Thi Minh Nguyen, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 7, pp. 1436-1447
Open Access | Times Cited: 43
Novel insights in cell cycle dysregulation during prostate cancer progression
Salma Ben‐Salem, Varadha Balaji Venkadakrishnan
Endocrine Related Cancer (2021) Vol. 28, Iss. 6, pp. R141-R155
Open Access | Times Cited: 34
Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer
Wanting Han, Mingyu Liu, Dong Han, et al.
Molecular Therapy (2022) Vol. 30, Iss. 4, pp. 1628-1644
Open Access | Times Cited: 24
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth
Michael D. Nyquist, Lisa S. Ang, Alexandra Corella, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 10
Open Access | Times Cited: 32
Androgens in prostate cancer: A tale that never ends
Zemin Hou, Shengsong Huang, Zhenfei Li
Cancer Letters (2021) Vol. 516, pp. 1-12
Closed Access | Times Cited: 31
Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer
Rajendra Kumar, Janet Mendonca, Olutosin Owoyemi, et al.
Cancer Research (2021) Vol. 81, Iss. 23, pp. 5948-5962
Open Access | Times Cited: 29
Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
Ilsa M. Coleman, Navonil De Sarkar, Colm Morrissey, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 14, pp. 3127-3140
Open Access | Times Cited: 21
A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance
Andrea Alegre‐Martí, Alba Jiménez-Panizo, Adrián Martínez-Tébar, et al.
Science Advances (2023) Vol. 9, Iss. 11
Open Access | Times Cited: 11
Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors
Xiong Zhang, Yatian Yang, Hongye Zou, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants
Mitchell G. Lawrence, Shivakumar Keerthikumar, Scott L. Townley, et al.
European Urology Focus (2025)
Open Access
ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer
Dong Han, Sujun Chen, Wanting Han, et al.
Cancer Research (2019) Vol. 79, Iss. 20, pp. 5260-5271
Open Access | Times Cited: 29
Patient-derived tumour models for personalized therapeutics in urological cancers
Arjanneke F. van de Merbel, Geertje van der Horst, Gabri van der Pluijm
Nature Reviews Urology (2020) Vol. 18, Iss. 1, pp. 33-45
Closed Access | Times Cited: 26
Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome
Xintao Qiu, Lisha G. Brown, Jennifer L. Conner, et al.
JCI Insight (2022) Vol. 7, Iss. 10
Open Access | Times Cited: 14
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
Michael T. Schweizer, Roman Gulati, Todd Yezefski, et al.
Prostate Cancer and Prostatic Diseases (2022) Vol. 26, Iss. 1, pp. 194-200
Open Access | Times Cited: 14
The future of patient-derived xenografts in prostate cancer research
Mitchell G. Lawrence, Renea A. Taylor, Georgia B. Cuffe, et al.
Nature Reviews Urology (2023) Vol. 20, Iss. 6, pp. 371-384
Open Access | Times Cited: 8
A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer
Jinghui Liu, Yue Zhao, Daheng He, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 4, pp. 101015-101015
Open Access | Times Cited: 8
Molecular determinants of response to high-dose androgen therapy in prostate cancer
Michael D. Nyquist, Alexandra Corella, Osama Mohamad, et al.
JCI Insight (2019) Vol. 4, Iss. 19
Open Access | Times Cited: 25
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth
Michael D. Nyquist, Lisa S. Ang, Alexandra Corella, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 12
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top